Comparing different lots of activated par- tial thromboplastin time reagent: analysis of two methods. Am J Clin Pathol. 1998;110(2):173-177. 75. Shojania AM, Tetreault J, Turnbull G. The variations between heparin sensitivity of different lots of activated partial thromboplastin time reagent produced by the same manufacturer. Am J Clin Pathol. 1988;89(1):19-23. 76. Zanke B, Shojania AM. Comparison of two aPTT methods of monitoring heparin therapy. aPTT ratio and heparin response of pooled normal plasma. Am J Clin Pathol. 1990;93(5):684-689. 77. Koerber JM, Smythe MA, Begle RL, Mattson JC, Kershaw BP, Westley SJ. Correlation of activated clotting time and activated partial thromboplastin time to plasma hep- arin concentration. Pharmacotherapy. 1999;19(8):922-931. 78. Manzato F, Mengoni A, Grilenzoni A, Lippi G. Evaluation of the activated partial thromboplastin time (aPTT) sen- sitivity to heparin using ve commercial reagents: impli- cations for therapeutic monitoring. Clin Chem Lab Med. 1998;36(12):975-980. 79. Raschke RA, Guidry JR, Foley MR. Apparent heparin resis- tance from elevated factor VIII during pregnancy. Obstet Gynecol. 2000;96(5 pt 2):804-806. 80. Rosborough TK. Comparison of anti-factor Xa heparin activity and activated partial thromboplastin time in 2,773 plasma samples from unfractionated heparin-treated patients. Am J Clin Pathol. 1997;108(6):662-668. 81. VollesDF,AncellCJ,MichaelKA,MullinsDM,HumphriesJE. Establishing an institution-speci c therapeutic range for heparin. Am J Health Syst Pharm. 1998;55(19):2002-2006. 82. Guidry JR, Raschke RA, Morkunas AR. Toxic effects of drugs used in the ICU. Anticoagulants and thrombolytics. Risks and bene ts [review]. Crit Care Clin. 1991;7(3): 533-554. 83. van den Besselaar AM, Meeuwisse-Braun J, Bertina RM. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples. Thromb Haemost. 1990; 63(1):16-23. 84. Cuker A, Raby A, Moffat KA, Flynn G, Crowther MA. Interlaboratory variation in heparin monitoring: Lessons from the Quality Management Program of Ontario coagula- tion surveys. Thromb Haemost. 2010;104(4):837-844. 51. 